Separately from the EMA line, the Datroway approval reinforces TROP2-directed ADC competition in TNBC where treatment options remain constrained. The approval expands the label to an earlier-line setting where patients are excluded from PD-1/PD-L1 inhibitor candidacy, carving out a defined subgroup for chemotherapy-replacement strategies. Clinicians are likely to treat the TROPION-Breast02 OS separation and higher objective response rate as the key datapoints for adoption discussions.